Страна: Нова Зеландия
Език: английски
Източник: Medsafe (Medicines Safety Authority)
Apomorphine hydrochloride hemihydrate 10 mg/mL;
CARSL Consulting
Apomorphine hydrochloride hemihydrate 10 mg/mL
10 mg/mL
Solution for injection
Active: Apomorphine hydrochloride hemihydrate 10 mg/mL Excipient: Hydrochloric acid Sodium hydroxide Sodium metabisulfite Water for injection
Prescription
Sanofi Chimie
Latest Regulatory Activity
Package - Contents - Shelf Life: Ampoule, glass, 5 mL - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light - Ampoule, glass, 2 mL - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light
1993-02-08
1 NEW ZEALAND DATASHEET 1 PRODUCT NAME MOVAPO ® Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Apomorphine hydrochloride 10 mg/mL injection solution 3 PHARMACEUTICAL FORM MOVAPO Injection is a clear, colourless or almost colourless sterile solution for injection, practically free from visible particles with a pH of 3.0 – 4.0. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications MOVAPO Injection is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with MOVAPO Injection should be undertaken in a specialist unit in a hospital setting. Conventional therapy should be continued during ‘on’ phases. 4.2 Dose and method of administration The optimal dosage of MOVAPO Injection has to be determined on an individual patient basis. Hospital admission under appropriate specialist supervision is advised when establishing a patient’s therapeutic regime. It is essential that the patient is established on the antiemetic domperidone for at least 48 - 72 hours prior to initiation of therapy. PATIENT SELECTION For patients in whom conventional therapy has failed, MOVAPO Injections are only considered to be suitable for Parkinson’s disease patients capable of recognising and anticipating ‘off’ phases in motor performance. Patients must be capable and motivated for MOVAPO Injection to be used effectively. Adult patients through all age ranges have been successfully managed with apomorphine injections. MOVAPO Injection is not recommended in children and adolescents up to 18 years of age (see section 4.3). The elderly are well represented in the population of patients with Parkinson’s disease and constitute a high proportion of those studied in clinical trials of apomorphine. The management of elderly patients treated with apomorphine has not differed from that of younger patients, except for the extra caution on commencing therapy, because of the risk of postural hypo Прочетете целия документ